TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Leishmaniasis
Researchers from Banaras Hindu University discuss findings in leishmaniasis
August 26th, 2008
"The aim of the present study was to compare the efficacy of a nano form of amphotericin B deoxycholate with that of conventional amphotericin B deoxycholate for the treatment of visceral leishmaniasis. We have formulated nanoparticles (10-20 nM) from amphotericin B deoxycholate (1-2 mc M) by applying high-pressure (150 argon) milling homogenization and have tested their efficacy in a J774A cell line and in hamsters," scientists in Varanasi, India report. "Parasite survival and tissue burden in spleen were evaluated for nano-amphotericin B and conventional amphotericin B. Both nano-amphotericin B and conventional amphotericin B were injected intraperitoneally at 5 mg/kg...
Source: TB & Outbreaks Week (2008-08-26)
|
